Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Inks $8.7B Deal to Acquire AveXis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Novartis Inks $8.7B Deal to Acquire AveXis

Novartis will pay $218 a share of AveXis in cash, an 88% premium to its closing price on April 6

By: Betsy Louda

, Contract Pharma

Novartis has entered an agreement to buy AveXis Inc., a gene therapy company, for $8.7 billion dollars as part of its neuroscience strategy.

 

The deal follows the recent sale of Novartis’s stake in its consumer health-care joint venture to GlaxoSmithKline PLC (GSK.LN) for $13 billion. 

 

Novartis will pay $218 a share of AveXis in cash, an 88% premium to its closing price on April 6, and intends to fund the acquisition with available cash and short-term borrowing.

 

Paul Hudson, chief executive officer of Novartis Pharmaceuticals, said, “Bringing AveXis on board would support both our ambition to be a leader in neurodegenerative diseases and our Neuroscience franchise priorities to strengthen our position in devastating pediatric neurological diseases such as SMA.”

 

AveXis is a gene-therapy company conducting several clinical studies for the treatment of spinal muscular atrophy, or SMA, an inherited neurodegenerative disease caused by a defect in a single gene. Their gene therapy candidate AVXS-101 has the potential to be the first one-time gene replacement therapy for SMA according to Novartis, and it currently has orphan drug designation from the U.S. Food and Drug Administration for the treatment of SMA.

 

The transaction was unanimously approved by the boards of the two companies, Novartis said, and the deal is expected to close in mid-2018.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics